Real-World Clinical Outcomes of Asthma Patients Switched from Reslizumab to Mepolizumab or Benralizumab

Overview

Journal Front Allergy

Specialty Allergy & Immunology

Date 2023 Jan 23

PMID 36686966

Authors

Laura J Walsh

Deborah Casey

Punitha Vairamani

Fiona Arnott

Barry J Plant

Desmond M Murphy

Affiliations

Soon will be listed here.

Abstract

Introduction: Approximately 3%-10% of asthma patients will remain uncontrolled despite maximum, optimal conventional therapy. Treatment of severe refractory asthma often involves the use of targeted biological therapy. Randomised controlled trials have shown improvements in clinical parameters with these treatments but real-world data is lacking.

Methods: The clinical parameters, frequency of exacerbations, number of hospital admissions, asthma control questionnaire score (ACQ), forced expiratory volume in one second (FEV) and maintenance oral corticosteroid (OCS) dose of twenty asthma patients switched from reslizumab to benralizumab or mepolizumab at 1 year prior and 6 months after switching were compared, with adjustments for time.

Results: The mean frequency of exacerbations (0.35 v 0.3) and the mean ACQ were essentially unchanged (1.6 v 1.5) following the switch. The number of hospital admissions was one in the 6 months post switch compared to one in 1-year pre switch. 25% of patients were on maintenance OCS before and after switching but one patient required an increased dose post switch resulting in an increase in the mean maintenance OCS dose (1.6 mg to 2.4 mg). The mean FEV was unchanged (80% v 77.9%) six months post switching. Regarding asthma control ( = 19), 47.4% were controlled pre and post switch (ACQ < 1.5), 36.8% remained uncontrolled despite switching, 10.5% improved control while 5.3% disimproved.

Conclusion: We present real-world clinical outcomes of asthma patients switched from reslizumab to either benralizumab or mepolizumab without a loss of clinical effectiveness in the majority.

References

Khatri S, Moore W, Gibson P, Leigh R, Bourdin A, Maspero J . Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2018; 143(5):1742-1751.e7. DOI: 10.1016/j.jaci.2018.09.033. View

Bleecker E, Wechsler M, FitzGerald J, Menzies-Gow A, Wu Y, Hirsch I . Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018; 52(4). PMC: 6203407. DOI: 10.1183/13993003.00936-2018. View

Ortega H, Liu M, Pavord I, Brusselle G, FitzGerald J, Chetta A . Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014; 371(13):1198-207. DOI: 10.1056/NEJMoa1403290. View

OReilly E, Casey D, Ibrahim H, McGrath A, McHugh T, Vairamani P . Real-World Clinical Outcomes in Asthmatic Patients Switched from Omalizumab to Anti-Interleukin-5 Therapy. J Asthma Allergy. 2022; 15:935-937. PMC: 9285523. DOI: 10.2147/JAA.S358321. View

Kuruvilla M, Lee F, Lee G . Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease. Clin Rev Allergy Immunol. 2018; 56(2):219-233. PMC: 6411459. DOI: 10.1007/s12016-018-8712-1. View

Pelaia C, Busceti M, Solinas S, Terracciano R, Pelaia G . Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study. Pulm Pharmacol Ther. 2018; 53:1-5. DOI: 10.1016/j.pupt.2018.09.006. View

Jackson D, Burhan H, Menzies-Gow A, Pfeffer P, Nanzer A, Garcia Gil E . Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use. J Allergy Clin Immunol Pract. 2022; 10(6):1534-1544.e4. DOI: 10.1016/j.jaip.2022.02.014. View

FitzGerald J, Bleecker E, Nair P, Korn S, Ohta K, Lommatzsch M . Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016; 388(10056):2128-2141. DOI: 10.1016/S0140-6736(16)31322-8. View

Bagnasco D, Menzella F, Caminati M, Caruso C, Guida G, Bonavia M . Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real-life observation. Allergy. 2019; 74(12):2539-2541. DOI: 10.1111/all.13937. View

10.

Gomez-Bastero Fernandez A, Medina Gallardo J, Delgado Romero J, Romero Falcon A, Benito Bernaldez C, Gallego Borrego J . Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma. J Asthma Allergy. 2022; 15:727-735. PMC: 9148608. DOI: 10.2147/JAA.S358705. View

11.

Mavissakalian M, Brady S . The Current State of Biologic Therapies for Treatment of Refractory Asthma. Clin Rev Allergy Immunol. 2020; 59(2):195-207. DOI: 10.1007/s12016-020-08776-8. View

12.

Carpagnano G, Scioscia G, Lacedonia D, Curradi G, Foschino Barbaro M . Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab. J Asthma Allergy. 2019; 12:83-90. PMC: 6407514. DOI: 10.2147/JAA.S196200. View

13.

Hashimoto S, Kroes J, Eger K, Mau Asam P, Hofstee H, Bendien S . Real-World Effectiveness of Reslizumab in Patients With Severe Eosinophilic Asthma - First Initiators and Switchers. J Allergy Clin Immunol Pract. 2022; 10(8):2099-2108.e6. DOI: 10.1016/j.jaip.2022.04.014. View

14.

Eger K, Kroes J, Ten Brinke A, Bel E . Long-Term Therapy Response to Anti-IL-5 Biologics in Severe Asthma-A Real-Life Evaluation. J Allergy Clin Immunol Pract. 2020; 9(3):1194-1200. DOI: 10.1016/j.jaip.2020.10.010. View

15.

Kavanagh J, dAncona G, Elstad M, Green L, Fernandes M, Thomson L . Real-World Effectiveness and the Characteristics of a "Super-Responder" to Mepolizumab in Severe Eosinophilic Asthma. Chest. 2020; 158(2):491-500. DOI: 10.1016/j.chest.2020.03.042. View

16.

Bagnasco D, Caminati M, Menzella F, Milanese M, Rolla G, Lombardi C . One year of mepolizumab. Efficacy and safety in real-life in Italy. Pulm Pharmacol Ther. 2019; 58:101836. DOI: 10.1016/j.pupt.2019.101836. View

17.

Martinez-Moragon E, Garcia-Moguel I, Nuevo J, Resler G . Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study). BMC Pulm Med. 2021; 21(1):417. PMC: 8684207. DOI: 10.1186/s12890-021-01785-z. View

18.

Nair P, Bardin P, Humbert M, Murphy K, Hickey L, Garin M . Efficacy of Intravenous Reslizumab in Oral Corticosteroid-Dependent Asthma. J Allergy Clin Immunol Pract. 2019; 8(2):555-564. DOI: 10.1016/j.jaip.2019.09.036. View

19.

Nolasco S, Crimi C, Pelaia C, Benfante A, Caiaffa M, Calabrese C . Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study. J Allergy Clin Immunol Pract. 2021; 9(12):4371-4380.e4. DOI: 10.1016/j.jaip.2021.08.004. View

20.

Mukherjee M, Forero D, Tran S, Boulay M, Bertrand M, Bhalla A . Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena. Eur Respir J. 2020; 56(4). DOI: 10.1183/13993003.00117-2020. View